Characteristics of patients who are initiated on long-acting buprenorphine (Buvidal®) in France: A retrospective cross-sectional study
The profile of patients initiated on Buvidal® in France was extremely similar to that of patients treated for OUD in France, either in terms of social or clinical features. While initial recommendations essentially underlined the interest of Buvidal® for some niche populations, the on-the-ground practice reveals a more widespread use, including for unrecovered patients, or patients treated with methadone.
Authors
- Benjamin Rolland (ORCID: https://orcid.org/0000-0002-8666-3635)
- Margaux Kosim (ORCID: https://orcid.org/0000-0002-9874-8978)
- Georges Brousse (ORCID: https://orcid.org/0000-0002-6514-5388)
- Alice Deschenau
- Mathieu Chappuy (ORCID: https://orcid.org/0000-0002-3176-6039)
- Lisa Blecha
- Benoît Trojak (ORCID: https://orcid.org/0000-0002-3315-882X)
- Julien Azuar
- Benjamin Touchon
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Institut Pascal (FR)
- Université de Bourgogne (FR)
- Université Clermont Auvergne (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Centre de Recherche en Neurosciences de Lyon (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospices Civils de Lyon (FR)
- Hôpital Fernand-Widal (FR)
- CHU Dijon Bourgogne (FR)
- Université Bourgogne Franche-Comté (FR)
- Pitié-Salpêtrière Hospital (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Centre Hospitalier Le Vinatier (FR)
- Hôpital Paul-Brousse (FR)
- Optimisation Thérapeutique en Neuropsychopharmacologie (FR)
Publication Details
- Journal
- Therapies
- Published
- 2024-10-05
- DOI
- https://doi.org/10.1016/j.therap.2024.09.003
- Citations
- 1
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.54
Funders
- Camurus Lipid Research Foundation